RecruitingPHASE1, PHASE2NCT06052436

Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)

Studying Infant acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hospital General Universitario Gregorio Marañon
Principal Investigator
Rafael Correa-Rocha, PhD
Hospital General Universitario Gregorio Marañon
Intervention
Allogeneic thyTreg 5.000.000(biological)
Enrollment
24 target
Eligibility
18-65 years · All sexes
Timeline
20232027

Study locations (1)

Collaborators

Instituto de Salud Carlos III

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06052436 on ClinicalTrials.gov

Other trials for Infant acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Infant acute respiratory distress syndrome

← Back to all trials